Department of Gastrointestinal Surgery, Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University, China.
FEBS Open Bio. 2021 Jun;11(6):1785-1798. doi: 10.1002/2211-5463.13160. Epub 2021 May 24.
The transcriptional repressor zinc finger homeobox 2 (ZHX2) is reported to regulate tumor progression in several human cancers, although little is known about its role in gastric cancer (GC). In the present study, we investigated the expression of ZHX2 and its relationship with the clinicopathological characteristics and prognosis of GC patients, and we also examined the effect of ZHX2 overexpression in GC cell lines. We used UALCAN (http://ualcan.path.uab.edu) and the Tumor Immune Estimation Resource (http://cistrome.org/TIMER) to examine ZHX2 mRNA expression, and also used Kaplan-Meier Plotter (https://kmplot.com) to determine whether ZHX2 expression was related to GC prognosis. Expression of ZHX2 protein was detected using immunohistochemical staining assays. Cell proliferation was evaluated using a cell counting kit-8 and colony formation assays, whereas apoptosis was examined by flow cytometry. Wound healing and transwell assays were used to detect cell migration and invasion. We also performed Gene Set Enrichment Analysis (https://www.gsea-msigdb.org) and used The Cancer Genome Atlas database (https://www.genome.gov/Funded-Programs-Projects/Cancer-Genome-Atlas) to examine the correlation of ZHX2 with immune infiltration. We report that ZHX2 is highly expressed in GC tissues and is significantly associated with clinical characteristics. Upregulation of ZHX2 predicted poor prognosis in GC. Furthermore, ZHX2 overexpression can promote the proliferation, invasion and migration, but inhibit apoptosis, of GC cells. High expression of ZHX2 in GC is correlated with the presence of infiltrating immune cells, including B cells, CD4 T cells, macrophages and dendritic cells. Our data suggest that high expression of ZHX2 in GC predicts poor prognosis. In addition, ZHX2 may promote malignant behaviors of GC cells, and immune infiltration might be related to the oncogenic role of ZHX2 in GC.
转录抑制因子锌指同源盒 2(ZHX2)被报道在几种人类癌症中调节肿瘤进展,尽管其在胃癌(GC)中的作用知之甚少。在本研究中,我们研究了 ZHX2 的表达及其与 GC 患者临床病理特征和预后的关系,并研究了 ZHX2 过表达对 GC 细胞系的影响。我们使用 UALCAN(http://ualcan.path.uab.edu)和肿瘤免疫估计资源(http://cistrome.org/TIMER)来检测 ZHX2 mRNA 表达,还使用 Kaplan-Meier Plotter(https://kmplot.com)来确定 ZHX2 表达是否与 GC 预后相关。使用免疫组织化学染色检测 ZHX2 蛋白的表达。通过细胞计数试剂盒-8 和集落形成测定评估细胞增殖,而通过流式细胞术检测细胞凋亡。通过划痕愈合和 Transwell 测定检测细胞迁移和侵袭。我们还进行了基因集富集分析(https://www.gsea-msigdb.org),并使用癌症基因组图谱数据库(https://www.genome.gov/Funded-Programs-Projects/Cancer-Genome-Atlas)来研究 ZHX2 与免疫浸润的相关性。我们报告 ZHX2 在 GC 组织中高度表达,并且与临床特征显著相关。ZHX2 上调预示 GC 预后不良。此外,ZHX2 过表达可促进 GC 细胞的增殖、侵袭和迁移,但抑制凋亡。GC 中 ZHX2 的高表达与浸润免疫细胞的存在相关,包括 B 细胞、CD4 T 细胞、巨噬细胞和树突状细胞。我们的数据表明,GC 中 ZHX2 的高表达预示着预后不良。此外,ZHX2 可能促进 GC 细胞的恶性行为,免疫浸润可能与 ZHX2 在 GC 中的致癌作用有关。